Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases

Patent metadata

Field	Value
Publication number	US-10201606-B2
Application number	US-201514952448-A
Country	US
Kind code	B2
Filing date	Nov 25, 2015
Priority date	Nov 26, 2014
Publication date	Feb 12, 2019
Grant date	Feb 12, 2019

Abstract

The invention provides a system that comprises pharmaceutical agents for use in immunotherapy for reducing the side-effects of an antigen-recognizing receptor against antigen-expressing non-target cells in an individual. The system includes an antigen-recognizing receptor that specifically recognizes an antigen on target cells and at least on one hematopoietic cell type in the individual. The antigen-recognizing receptor is exemplified by chimeric antigen receptors (CAR) be expressed on the surface of an immune effector cells. The system also includes hematopoietic cells resistant to recognition of the same antigen by the antigen-recognizing receptor.

First claim

The invention claimed is:

1. A method of immunotherapy of a patient in need thereof, comprising:
(a) administering to the patient a population of immune effector cells that express on their surface a recombinant antigen-recognizing receptor that specifically binds human CD20 antigen, wherein the CD20 antigen is expressed on target cells in the patient and on at least one type of non-target hematopoietic cells in the patient; and
(b) administering to the patient a population of hematopoietic cells, a plurality of which have been recombinantly altered to express a human CD20 antigen in a form that has been altered to include one or more amino acid deletions or substitutions in SEQ. ID NO:3 such that the antigen-recognizing receptor on the immune effector cells has an affinity for the altered CD20 antigen that is at least 10-fold less than its affinity for the native CD20 antigen.

2. The method of claim 1 , wherein
the antigen-recognizing receptor on the immune effector cells has an affinity for the altered CD20 antigen that is 1000-fold to 100,000-fold less than its affinity for the native CD20 antigen.

3. The method of claim 1 , wherein the antigen-recognizing receptor is a chimeric antigen receptor (CAR) comprising an antibody variable region specific for the CD20 antigen in tandem with a T cell stimulatory domain.

4. The method of
claim 2 , wherein the T cell stimulatory domain is a CD3ξ domain.

5. The method of claim 1 , wherein the patient is concurrently administered with both the population of immune effector cells and the population of hematopoietic cells.

6. The method of claim 1 , wherein the hematopoietic cells are hematopoietic stem cells or hematopoietic progenitor cells.

7. The method of claim 1 , wherein the immune effector cells and the hematopoietic cells are both autologous to the patient.

8. The method of claim 3 , wherein the CAR comprises SEQ. ID NO:1 (V H ) and SEQ. ID NO:2 (V L ).

9. The method of claim 1 , wherein
the hematopoietic cells express a splice variant of CD20 that the antigen-recognizing receptor on the immune effector cells does not bind.

10. The method of claim 1 , wherein the form of CD20 expressed by the hematopoietic cells comprises SEQ. ID NO:3 with an amino acid substitution at position 170 and/or position 172.

11. The method of claim 1 , wherein the target cells are a type of hematopoietic cell that expresses the CD20 antigen.

12. A method of reducing the side effects of immunotherapy against antigen-expressing non-target cells in a patient,
wherein the immunotherapy comprises administering to the patient a population of immune effector cells that express a chimeric antigen receptor (CAR), wherein the CAR comprises an antibody variable region that is specific for CD20 antigen expressed by target cells in the patient, in tandem with a T cell signaling domain;
wherein the method of reducing side effects comprises:
(a) obtaining a pharmaceutical composition comprising a population of hematopoietic cells that express the same antigen that is expressed by the target cells, but in a form that has been recombinantly altered to include one or more amino acid deletions or substitutions in SEQ. ID NO:3 that inhibit binding of the altered CD20 by the CAR; and
(b) administering the hematopoietic cells to the patient before, during, or after administration of the immune effector cells.

Assignees

• Miltenyi Biotec Gmbh

Inventors

• Lutteropp Michael
• Richter Anne
• Kaiser Andrew
• Assenmacher Mario
• Miltenyi Stefan

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61K2035/124

  the cells being hematopoietic, bone marrow derived or blood cells · CPC title

• A61K35/12

  Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00) · CPC title

• A61K38/1774 Primary

  Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules) · CPC title

• A61K39/3955 Primary

  against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title